The obesity drug pipeline remains robust, with next-generation therapies and novel mechanisms progressing through multiple phases of clinical development
Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives
Voyxact requires clinical PA
Oral GLP-1: The Next Distribution ShiftBut Not the Torch Pass Yet The Obesity Inflection: When GLP-1 Became a Franchise A decade ago, GLP-1 was still largely framed as a diabetes class with incremental metabolic benefits
This enzymatic reaction consumes both nicotinamide and SAM, leading to depletion of NAD+ storesa critical coenzyme required for cellular energy production, DNA repair, and metabolic regulation
Health Canada considers NHP compounding within a practitioner-patient relationship distinct from manufacturing and not subject to the same regulatory oversight (new window)